PubRank
Search
About
Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer (PROTECT)
Clinical Trial ID NCT00779402
PubWeight™ 11.81
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT00779402
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Novel therapies for metastatic castrate-resistant prostate cancer.
J Natl Cancer Inst
2011
1.98
2
Trial watch: Dendritic cell-based interventions for cancer therapy.
Oncoimmunology
2012
1.51
3
Clinical opportunities and challenges in targeting tumour dormancy.
Nat Rev Clin Oncol
2012
1.26
4
Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions.
Clin Adv Hematol Oncol
2013
1.22
5
Emerging novel therapies in the treatment of castrate-resistant prostate cancer.
Can Urol Assoc J
2011
1.04
6
Prostate cancer vaccines: Update on clinical development.
Oncoimmunology
2013
0.98
7
Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.
Urology
2013
0.82
8
Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.
Ther Clin Risk Manag
2014
0.80
9
Immune response to sipuleucel-T in prostate cancer.
Cancers (Basel)
2012
0.79
10
Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm.
Oncoimmunology
2015
0.78
11
Immunotherapy for prostate cancer: False promises or true hope?
Cancer
2016
0.78
Next 100